Approved indications: Cabometyx is FDA‑approved for advanced renal cell carcinoma (alone or in combination with nivolumab as first‑line treatment), hepatocellular carcinoma previously treated with sorafenib, and for adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, as well as previously treated, unresectable, well‑differentiated pancreatic and extra‑pancreatic neuroendocrine tumors.

How well it works: In clinical trials, Cabometyx delayed tumor growth and improved outcomes compared with older standard drugs or placebo in these cancers, often roughly doubling median progression‑free survival in renal cell carcinoma and hepatocellular carcinoma and significantly prolonging progression‑free survival in differentiated thyroid cancer and neuroendocrine tumors.

Onset and expectations: Doctors typically assess benefit with scans every 8–12 weeks; when Cabometyx is effective, many patients experience tumor shrinkage or disease stabilization within the first few months, and benefit can last many months or longer, though it does not work for everyone and cancers may eventually progress.

Off‑label use: Cabozantinib has activity in several other tumor types, so Cabometyx or the related capsule product (Cometriq) may sometimes be used off‑label in selected advanced cancers based on early or evolving evidence, but these uses are not FDA‑approved and the strength of supporting data varies by cancer type.

Comparison with similar drugs: Compared with other VEGFR‑targeting tyrosine kinase inhibitors, Cabometyx is among the more potent options in renal cell carcinoma and has unique approvals in hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; its efficacy is balanced by a side‑effect profile that is broadly similar in type but can be more intense, requiring frequent dose reductions and careful management.

How to take it: Cabometyx tablets are taken by mouth once daily on an empty stomach, at least 1 hour before or 2 hours after eating; the tablets should be swallowed whole with water, not crushed, chewed, or split, and are usually taken at the same time each day.

Typical doses by condition: For most adults with renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC), and for adults and adolescents 12 years and older with differentiated thyroid cancer or neuroendocrine tumors weighing at least 40 kg, the usual dose is 60 mg once daily; when used in combination with nivolumab for advanced RCC, the Cabometyx dose is typically 40 mg once daily, and adolescents 12 years and older who weigh under 40 kg usually receive 40 mg once daily.

Individual dose adjustments: Doctors often reduce the dose (for example from 60 mg to 40 mg or 20 mg) or interrupt treatment temporarily to manage side effects, and they may change the dose when Cabometyx is given with strong CYP3A4 inhibitors or inducers, or in people with moderate liver impairment.

Special instructions: Treatment is generally continued as long as the cancer is controlled and side effects are manageable; Cabometyx is usually stopped at least 3 weeks before planned major or dental surgery and restarted no sooner than 2 weeks after major surgery and only once wounds have adequately healed.

Missed dose: If a dose is missed, it can be taken later the same day only if there are at least 12 hours before the next scheduled dose; if it is less than 12 hours until the next dose, the missed dose should be skipped and the regular schedule resumed without doubling up.

Overdose: Taking more than the prescribed amount can lead to severe side effects such as intense diarrhea, dangerous blood pressure elevations, bleeding, or organ problems, and requires immediate medical help, typically by contacting emergency services or a poison control center for guidance.

Common side effects: Very common reactions (often affecting more than 1 in 5 people) include diarrhea, fatigue or weakness, decreased appetite and weight loss, nausea and vomiting, mouth soreness, palmar‑plantar erythrodysesthesia (hand‑foot redness, pain, or peeling), high blood pressure, constipation, and changes in taste; these usually begin in the first days to weeks of treatment and can range from mild to severe.

Serious risks requiring urgent attention: Cabometyx can cause severe bleeding, gastrointestinal perforation (a hole) or fistulas (abnormal connections between organs), blood clots (including heart attack, stroke, or pulmonary embolism), heart failure, severe hypertension or hypertensive crisis, liver injury (especially with nivolumab), kidney problems including heavy protein in the urine, osteonecrosis of the jaw, poor wound healing, and a rare brain condition called reversible posterior leukoencephalopathy syndrome; sudden severe pain, swelling, shortness of breath, chest pain, confusion, seizures, heavy bleeding, or signs of infection warrant immediate medical care.

Warnings and precautions: Cabometyx can harm an unborn baby, so effective contraception is needed during treatment and for at least 4 months after the last dose, and breastfeeding should be avoided during treatment and for at least 4 months afterward; it is not established for children under 12 years, and people with moderate liver impairment need dose reduction while those with severe liver impairment generally should not receive it.

Other medical conditions: Extra caution and closer monitoring are needed in people with uncontrolled high blood pressure, recent or active significant bleeding, blood clots, heart disease, liver disease, significant kidney disease, low calcium, dental disease or planned invasive dental work, or who are scheduled for major surgery, because Cabometyx can worsen bleeding, clotting, heart function, blood pressure, jaw health, and wound healing.

Relative safety versus other options: The overall safety profile is similar to other VEGFR tyrosine kinase inhibitors, but diarrhea, hand‑foot syndrome, hypertension, and fatigue are particularly prominent and dose reductions are common; with good supportive care and regular monitoring, many patients can remain on therapy long term.

Side‑effect monitoring and reporting: Patients are usually monitored with regular blood pressure checks, blood tests (for liver, kidney, thyroid function, electrolytes, and blood counts), urine protein checks, and symptom review; suspected serious side effects can be reported to the FDA MedWatch program or the manufacturer, and updated safety information is available through the FDA and the Cabometyx prescribing information.

Metabolism and key drug interactions: Cabometyx is broken down mainly by the liver enzyme CYP3A4, so strong CYP3A4 inhibitors (such as certain antifungals, some HIV and hepatitis C medicines, and some macrolide antibiotics) can raise cabozantinib levels and often require a dose reduction, while strong or moderate CYP3A4 inducers (such as rifampin, certain seizure medicines, or St. John’s wort) can lower cabozantinib levels and may require a dose increase or avoidance of the combination.

Other medicines and substances: Because Cabometyx increases bleeding and clotting risks, extra care is needed when it is used with blood thinners (like warfarin, DOACs, or heparins), antiplatelet drugs (such as aspirin or clopidogrel), and NSAIDs; combining with other blood‑pressure–raising or heart‑affecting medicines may also need closer monitoring, and patients should review all prescription drugs, OTC medicines, vitamins, herbal products (especially St. John’s wort), and supplements with their oncology team.

Food, alcohol, and procedures: Cabometyx must be taken fasting (at least 1 hour before or 2 hours after food) to keep absorption predictable; moderate alcohol use should be discussed with the treating physician, particularly in people with liver disease, and the drug is usually held for several weeks around major or invasive dental surgery because of bleeding and wound‑healing risks.

Conditions requiring caution: Use requires particular caution or may be inappropriate in people with recent significant bleeding, high risk of GI perforation or fistula (such as certain bowel conditions, prior radiation, or tumors invading hollow organs), uncontrolled hypertension, serious heart disease, recent blood clots, severe liver impairment, or poorly healing wounds or major planned surgery.

Monitoring needs: During treatment, clinicians typically monitor blood pressure, complete blood counts, liver and kidney function, thyroid tests, calcium and other electrolytes, and urine protein, and they assess for heart failure or fluid overload; ECGs may be obtained in patients with cardiac risk factors or concerning symptoms, and imaging scans are done periodically to track cancer response.

Q: What is Cabometyx used for?
A: Cabometyx is an oral targeted therapy used to treat certain advanced cancers, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) previously treated with sorafenib, and some advanced thyroid and neuroendocrine tumors in adults and in children 12 years and older.

Q: How long can I stay on Cabometyx?
A: Treatment usually continues as long as it is controlling the cancer and side effects remain manageable, which for some people may be many months or longer, but it is stopped if the cancer clearly progresses or toxicity becomes unacceptable.

Q: When should I take Cabometyx in relation to meals?
A: Take Cabometyx once a day on an empty stomach, at least 1 hour before eating or at least 2 hours after eating, and try to take it at the same time each day.

Q: What happens if I miss a dose?
A: If you miss a dose and there are at least 12 hours until your next scheduled dose, you can take it when you remember; if there are fewer than 12 hours left, skip the missed dose and take your next dose at the regular time without doubling up.

Q: Are the Cabometyx tablets the same as cabozantinib capsules (Cometriq)?
A: No, Cabometyx tablets and Cometriq capsules are different products with different dosing and are not interchangeable, so you should only take the exact formulation and strength prescribed for you.

Q: What side effects should I call my doctor about right away?
A: Contact your care team urgently or seek emergency help if you have severe or sudden chest pain, trouble breathing, severe headache, confusion, seizures, heavy or unusual bleeding, severe abdominal pain, black or bloody stools, coughing up blood, signs of infection with fever and chills, or any rapidly worsening symptom.

Storage: Keep Cabometyx tablets at room temperature (generally 68°F to 77°F / 20°C to 25°C), in the original tightly closed container, away from moisture, heat, and direct light, and out of reach of children and pets.

Handling: Do not crush, chew, or split the tablets; caregivers who are pregnant or breastfeeding should avoid prolonged direct contact with broken tablets or dust and wash hands after handling the bottle.

Disposal: Do not flush tablets down the toilet or throw them loose into household trash; instead, use a community drug take-back program when available or follow pharmacist or local waste authority instructions for mixing unused tablets with an unappealing substance (such as used coffee grounds or cat litter), sealing in a bag or container, and discarding in household trash.